Item 8.01 Other Events.
On June 22, 2022, Athira Pharma, Inc. (the “Company”) issued a press release
announcing the topline results from the Company’s exploratory ACT-AD Phase 2
study of fosgonimeton in mild-to-moderate Alzheimer’s Disease.
A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
The Company will host a live webcast to discuss the ACT-AD results in greater
detail at 8:30 a.m. ET today, Wednesday, June 22, 2022. To access the live
webcast, please visit the “Events and Presentations” page within the Investors
section of the Athira website
https://investors.athira.com/news-and-events/events-and-presentations. As part
of the webcast, the Company will present certain slides relating to the ACT-AD
results, which slides are attached as Exhibit 99.2 hereto.
The information in Item 7.01 of this Current Report on Form 8-K, including the
slides to be used during the webcast and attached as Exhibit 99.2 hereto, are
being furnished and not filed pursuant to Item 7.01 of Form 8-K. Such
information shall not be deemed to be “filed” for purposes of Section 18 of the
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities of that section, and shall not be deemed to be incorporated by
reference into any of the Company’s filings under the Securities Act of 1933, as
amended, or the Exchange Act whether made before or after the date hereof and
regardless of any general incorporation language in such filings, except to the
extent expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
Exhibit No. Description 99.1 Athira Pharma, Inc. press release dated June 22, 2022 . 99.2 Athira Pharma, Inc. presentation slides . 104 Cover Page Interactive Data File (formatted as Inline XBRL)
© Edgar Online, source Glimpses